Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

BUY
$76.22 - $98.51 $1.74 Million - $2.25 Million
22,865 New
22,865 $2.2 Million
Q2 2022

Aug 05, 2022

SELL
$71.48 - $86.85 $665,621 - $808,747
-9,312 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$74.28 - $92.69 $237,398 - $296,237
3,196 Added 52.26%
9,312 $718,000
Q4 2021

Feb 14, 2022

BUY
$71.72 - $91.47 $438,639 - $559,430
6,116 New
6,116 $540,000
Q3 2021

Nov 12, 2021

SELL
$74.77 - $85.47 $384,691 - $439,743
-5,145 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$75.51 - $84.79 $380,268 - $427,002
-5,036 Reduced 49.46%
5,145 $429,000
Q1 2021

May 04, 2021

BUY
$74.73 - $90.69 $754,623 - $915,787
10,098 Added 12166.27%
10,181 $769,000
Q3 2020

Nov 03, 2020

BUY
$71.87 - $131.03 $5,965 - $10,875
83 New
83 $6,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Cowen And Company, LLC Portfolio

Follow Cowen And Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cowen And Company, LLC with notifications on news.